| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.2 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.23 | 0.2 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |